NCT06517498

Brief Summary

The goal of this observational study is to learn the patient journey, disease burden, living situation, quality of life and etc. in patients with Facioscapulohumeral Muscular Dystrophy in all sex/gender and age groups. The main questions it aims to answer are:

  1. 1.What's the patient journey of patients with Facioscapulohumeral Muscular Dystrophy?
  2. 2.How does Facioscapulohumeral Muscular Dystrophy burden the patients?
  3. 3.How's the quality of life of patients with Facioscapulohumeral Muscular Dystrophy?
  4. 4.fill a questionnaire.
  5. 5.be interviewed and answer questions about their illness experience, economic burden, quality of life and etc.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
300

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2024

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2024

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

July 9, 2024

Completed
15 days until next milestone

First Posted

Study publicly available on registry

July 24, 2024

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2025

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2025

Completed
Last Updated

July 24, 2024

Status Verified

July 1, 2024

Enrollment Period

1 year

First QC Date

July 9, 2024

Last Update Submit

July 18, 2024

Conditions

Keywords

Facioscapulohumeral Muscular DystrophyDisease BurdenQuality of LifeLiving Situation

Outcome Measures

Primary Outcomes (4)

  • EQ-5D

    EQ-5D questionnaires will be used to measure the quality of life of the patients. The questionnaires consist of two main parts: Descriptive System and Visual Analog Scale. Descriptive System includes Mobility, Self-Care, Usual Activities, Pain/Discomfort and Anxiety/Depression, each with 5 levels for adults and 3 levels for children. Visual Analog Scalerequires patients to rate their overall health on a scale from 0 to 100, where 0 represents "the worst health you can imagine" and 100 represents "the best health you can imagine." In the end, an index value will be calculated that reflects the patient's overall health status.

    1 year

  • Anxiety Level

    The Self-Rating Anxiety Scale will be used to measure the anxiety level of the patients. It consists of 20 items, each describing a common symptom of anxiety. Each item is rated on a 4-point Likert scale. The total score ranges from 20 to 80. In doing so, the anxiety level of the patients can be screened.

    1 year

  • Economic Burden

    Questions will designed to explore the economic burden of the patients. Questions include direct and indirect medical costs over the past year, annual incomes, accumulated treatment costs and debts. Each questions include 7 levels. Besides, whether they have public health insurance and commercial insurance will be asked to discover how much the costs can be covered.

    1 year

  • Disease Burden

    Questions will designed to explore the disease burden of the patients. Questions include the influence of the disease on respiratory system, dry eyes, whistle, deglutition, speaking and walking. Each question contains 5 levels.

    1 year

Study Arms (1)

Patients With Facioscapulohumeral Muscular Dystrophy

No intervention will be administered

Other: No Intervention

Interventions

No Intervention will be conducted

Patients With Facioscapulohumeral Muscular Dystrophy

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study will focus on individuals diagnosed as Facioscapulohumeral Muscular Dystrophy in all sex and age groups.

You may qualify if:

  • Having been diagnosed as Facioscapulohumeral Muscular Dystrophy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Health Science Center of Xi'an Jiaotong University

Xi'an, Shaanxi, 710049, China

RECRUITING

MeSH Terms

Conditions

Muscular Dystrophy, Facioscapulohumeral

Condition Hierarchy (Ancestors)

Muscular DystrophiesMuscular Disorders, AtrophicMuscular DiseasesMusculoskeletal DiseasesNeuromuscular DiseasesNervous System DiseasesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Officials

  • Wenjing Ji, PhD

    Xi'an Jiaotong University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Wenjing Ji, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
ECOLOGIC OR COMMUNITY
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

July 9, 2024

First Posted

July 24, 2024

Study Start

March 1, 2024

Primary Completion

March 1, 2025

Study Completion

July 1, 2025

Last Updated

July 24, 2024

Record last verified: 2024-07

Data Sharing

IPD Sharing
Will not share

No IPD will be shared

Locations